使用 EpiXs、NGCal 和 PSTAR 软件研究某些免疫疗法药物的伽马、中子和质子相互作用参数

IF 1.4 3区 化学 Q4 CHEMISTRY, INORGANIC & NUCLEAR
Gangadharayya Hiremath, Vishwanath Singh, Narasimha Ayachit, Nagappa Badiger
{"title":"使用 EpiXs、NGCal 和 PSTAR 软件研究某些免疫疗法药物的伽马、中子和质子相互作用参数","authors":"Gangadharayya Hiremath, Vishwanath Singh, Narasimha Ayachit, Nagappa Badiger","doi":"10.1515/ract-2023-0255","DOIUrl":null,"url":null,"abstract":"In proton therapy, the protons are used to destroy the cancer cells efficiently at the Bragg peak without much damage to normal cells. The protons can also produce neutrons, protons, and high-energy gamma rays through nuclear reactions with cancerous and healthy tissues as well as with beamline components. The effective observed dose in the therapy is enhanced due to the interaction of nuclear particles with cancerous tissues. Such nuclear particles can have several effects on drugs used in immunotherapy, such as immunotherapy in combination with proton therapy, which has been used to treat cancer. In the present investigations, the gamma, neutron, and protons interaction parameters of some immunotherapy drugs, such as dostarlimab, atezolizumab, ipilimumab, nivolumab, and pembrolizumab, are determined by using EpiXs, NGCal, and PSTAR software. It is found that the EBF and EABF for all selected immunotherapy drugs increase with increasing penetration depth, peaking at 100 keV. The peaking is more symmetric at a higher penetration depth of 40 mfp than at a lower one of 1 mfp. At lower energies of gamma photons, the EBF values increase exponentially, and at higher energies, they increase linearly with increasing penetration depth for all selected drugs. Mass attenuation factors are slightly higher for thermal neutrons than for fast neutrons for selected immunotherapeutic drugs, indicating that thermal neutrons more actively participate in these drugs than fast neutrons. The mass attenuation factor for both fast and thermal neutrons increases with increasing weight percentages of hydrogen and is found to be higher for thermal neutrons. This is the first study in the literature to investigate the radiation interaction parameters for immunotherapy drugs, and it is helpful in radiation therapy and dosimetry.","PeriodicalId":21167,"journal":{"name":"Radiochimica Acta","volume":null,"pages":null},"PeriodicalIF":1.4000,"publicationDate":"2024-05-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Study of gamma, neutron, and proton interaction parameters of some immunotherapy drugs using EpiXs, NGCal, and PSTAR software\",\"authors\":\"Gangadharayya Hiremath, Vishwanath Singh, Narasimha Ayachit, Nagappa Badiger\",\"doi\":\"10.1515/ract-2023-0255\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"In proton therapy, the protons are used to destroy the cancer cells efficiently at the Bragg peak without much damage to normal cells. The protons can also produce neutrons, protons, and high-energy gamma rays through nuclear reactions with cancerous and healthy tissues as well as with beamline components. The effective observed dose in the therapy is enhanced due to the interaction of nuclear particles with cancerous tissues. Such nuclear particles can have several effects on drugs used in immunotherapy, such as immunotherapy in combination with proton therapy, which has been used to treat cancer. In the present investigations, the gamma, neutron, and protons interaction parameters of some immunotherapy drugs, such as dostarlimab, atezolizumab, ipilimumab, nivolumab, and pembrolizumab, are determined by using EpiXs, NGCal, and PSTAR software. It is found that the EBF and EABF for all selected immunotherapy drugs increase with increasing penetration depth, peaking at 100 keV. The peaking is more symmetric at a higher penetration depth of 40 mfp than at a lower one of 1 mfp. At lower energies of gamma photons, the EBF values increase exponentially, and at higher energies, they increase linearly with increasing penetration depth for all selected drugs. Mass attenuation factors are slightly higher for thermal neutrons than for fast neutrons for selected immunotherapeutic drugs, indicating that thermal neutrons more actively participate in these drugs than fast neutrons. The mass attenuation factor for both fast and thermal neutrons increases with increasing weight percentages of hydrogen and is found to be higher for thermal neutrons. This is the first study in the literature to investigate the radiation interaction parameters for immunotherapy drugs, and it is helpful in radiation therapy and dosimetry.\",\"PeriodicalId\":21167,\"journal\":{\"name\":\"Radiochimica Acta\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":1.4000,\"publicationDate\":\"2024-05-08\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Radiochimica Acta\",\"FirstCategoryId\":\"92\",\"ListUrlMain\":\"https://doi.org/10.1515/ract-2023-0255\",\"RegionNum\":3,\"RegionCategory\":\"化学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"CHEMISTRY, INORGANIC & NUCLEAR\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Radiochimica Acta","FirstCategoryId":"92","ListUrlMain":"https://doi.org/10.1515/ract-2023-0255","RegionNum":3,"RegionCategory":"化学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"CHEMISTRY, INORGANIC & NUCLEAR","Score":null,"Total":0}
引用次数: 0

摘要

在质子治疗中,质子用于在布拉格峰有效地摧毁癌细胞,而不会对正常细胞造成太大伤害。质子还可以通过与癌组织、健康组织以及光束线组件的核反应产生中子、质子和高能伽马射线。由于核粒子与癌组织的相互作用,治疗中的有效观察剂量会增加。这种核粒子会对免疫疗法中使用的药物产生多种影响,例如与质子疗法相结合的免疫疗法,这种疗法已被用于治疗癌症。本研究利用 EpiXs、NGCal 和 PSTAR 软件测定了一些免疫治疗药物(如多司他利单抗、阿特珠单抗、伊匹单抗、尼维单抗和彭博罗珠单抗)的伽马、中子和质子相互作用参数。结果发现,所有选定免疫疗法药物的 EBF 和 EABF 都随着穿透深度的增加而增加,在 100 keV 处达到峰值。在穿透深度为 40 mfp 时,峰值比穿透深度为 1 mfp 时更对称。在较低的伽马光子能量下,所有选定药物的 EBF 值呈指数增长,而在较高的能量下,随着穿透深度的增加,EBF 值呈线性增长。对于选定的免疫治疗药物,热中子的质量衰减系数略高于快中子,这表明热中子比快中子更积极地参与这些药物的治疗。快中子和热中子的质量衰减系数都随着氢重量百分比的增加而增加,并且发现热中子的质量衰减系数更高。这是文献中首次研究免疫治疗药物的辐射相互作用参数,有助于放射治疗和剂量测定。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Study of gamma, neutron, and proton interaction parameters of some immunotherapy drugs using EpiXs, NGCal, and PSTAR software
In proton therapy, the protons are used to destroy the cancer cells efficiently at the Bragg peak without much damage to normal cells. The protons can also produce neutrons, protons, and high-energy gamma rays through nuclear reactions with cancerous and healthy tissues as well as with beamline components. The effective observed dose in the therapy is enhanced due to the interaction of nuclear particles with cancerous tissues. Such nuclear particles can have several effects on drugs used in immunotherapy, such as immunotherapy in combination with proton therapy, which has been used to treat cancer. In the present investigations, the gamma, neutron, and protons interaction parameters of some immunotherapy drugs, such as dostarlimab, atezolizumab, ipilimumab, nivolumab, and pembrolizumab, are determined by using EpiXs, NGCal, and PSTAR software. It is found that the EBF and EABF for all selected immunotherapy drugs increase with increasing penetration depth, peaking at 100 keV. The peaking is more symmetric at a higher penetration depth of 40 mfp than at a lower one of 1 mfp. At lower energies of gamma photons, the EBF values increase exponentially, and at higher energies, they increase linearly with increasing penetration depth for all selected drugs. Mass attenuation factors are slightly higher for thermal neutrons than for fast neutrons for selected immunotherapeutic drugs, indicating that thermal neutrons more actively participate in these drugs than fast neutrons. The mass attenuation factor for both fast and thermal neutrons increases with increasing weight percentages of hydrogen and is found to be higher for thermal neutrons. This is the first study in the literature to investigate the radiation interaction parameters for immunotherapy drugs, and it is helpful in radiation therapy and dosimetry.
求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Radiochimica Acta
Radiochimica Acta 化学-核科学技术
CiteScore
2.90
自引率
16.70%
发文量
78
审稿时长
6 months
期刊介绍: Radiochimica Acta publishes manuscripts encompassing chemical aspects of nuclear science and technology.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信